PharmTech spoke with Tara Dougal, event director for pharma at Informa Markets, about trends impacting the pharmaceutical industry and how CPHI Milan is addressing these areas this year.
|Articles|December 2, 2016
- Pharmaceutical Technology-12-02-2016
- Volume 40
- Issue 12
Pharmaceutical Technology, December 2016 Issue (PDF)
Click the title above to open the Pharmaceutical Technology December 2016 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 10 years ago
Options in Employee Trainingalmost 10 years ago
Biosimilars Supporting Contract Manufacturers’ Growthalmost 10 years ago
Airlocks for cGMP Facilitiesalmost 10 years ago
Evaluating Mixing in a Single-Use Bioprocessing Systemalmost 10 years ago
Shrink Banders for Labeling Applicationsalmost 10 years ago
Chromatograph Enables Fast Recovery of Target Compoundsalmost 10 years ago
Automated Microscope for Multimodal Imagingalmost 10 years ago
From Bitter to Sweet: Developing a User-Friendly Painkilleralmost 10 years ago
Nurturing the Relationship Between Industry and Regulatorsalmost 10 years ago
Getting involved with pharma standardsAdvertisement
Related to this article
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
FDA opens applications for its Expedited IND Pilot, pairing sponsors with qualified research institutions to test rolling CMC review ahead of first-in-human trials.
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
Karthik Iyer, Eli Lilly, details an AI system linking GMP findings, audits, and deviations for cited, inspection-ready regulatory intelligence.
Advertisement
Advertisement